Approximately 60% of the tumors were adenocarcinoma, and 30% were the type of squamous cell, and there was 21 (17.5%) of 120 patients with some mutations for adenocarcinoma, which included 17 (14.2%) with EGFR mutations, and 4 (3.3%) with EML4-ALK rearrangements (detailed data were not presented). Here, ALK is linked to adenocarcinoma.